Status:
TERMINATED
A Study of LY3435151 in Participants With Solid Tumors
Lead Sponsor:
Eli Lilly and Company
Conditions:
Solid Tumor
Triple-negative Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.
Eligibility Criteria
Inclusion
- Participant must have certain types of cancer, which your study doctor will discuss with you
- Participant must have stopped other forms of treatment for cancer, which your study doctor will discuss with you
- Participant must be able and willing to provide a sample of your tumor before beginning treatment and once while on treatment. For certain tumor types, the outcome of the biopsy may exclude you from the study treatment (for Phase 1b)
- Participant must agree to use birth control
- Participant must have progressed through or are intolerant to therapies with known clinical benefit, which your study doctor will discuss with you
Exclusion
- Participant must not have a history of tuberculosis, uncontrolled HIV or uncontrolled hepatitis B or C virus infection
- Participant must not have an autoimmune disease, which your study doctor will discuss with you
- Participant must not use corticosteroids, which your study doctor will discuss with you
- Participant must not have heart disease, Crohn's disease or brain cancer
- Participant must not be pregnant or breastfeeding
Key Trial Info
Start Date :
October 28 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 5 2020
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT04099277
Start Date
October 28 2019
End Date
March 5 2020
Last Update
August 31 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
2
National Cancer Center Hospital
Chuo-Ku, Tokyo, Japan, 104-0045